Medical Affluent to provide millions of patients with more effective treatments for serious and widespread diseases.
Mission and Vision
Patient health and unmet medical needs in structural heart disease, vascular therapy and urology are a daily concern for Affluent Medical. Millions of patients around the world are suffering and cannot always find optimal therapies and achieve a good quality of life with their poor prognosis. Our goal is to help patients worldwide to live longer healthier lives.
We believe that an alternative approach is possible that factors the capabilities of the human body and complex physiology into the design of products that reduce the risk of early or late disease recurrence.
We are committed to offering the best available therapies worldwide for hitherto largely unmet needs in terms of widespread and critical diseases.
A deep understanding of physiology and experience attained with surgeons is helping us to design a new generation of minimally invasive prostheses aimed at mimicking human anatomy and restoring native physiology for critical functions.
Our approach heralds a new era for cardiovascular and urological therapies. The combination of our highly talented team and deep expertise will enable us to lead this major shift toward more physiological therapies.
Our minimally invasive implants undergo strict scientific and clinical testing in collaboration with top medical centers around the globe. We are also seeking to rein in healthcare expenditure, which represents a major challenge for public and private health systems alike.
Expertise and know-how
Affluent Medical strives to provide best-in-class minimally invasive implants. We leverage know-how concerning transcatheter and flow control technologies to achieve the following key benefits:
- Mimicry of anatomy and restoration of physiology
- Adjustability to meet individual patient needs
- Minimally invasive implant procedures
- Optimized and biocompatible components.
As a technology-focused company, we have developed a strong key intellectual property portfolio, supported by Freedom-to-Operate (FTO) studies and protected until 2038. All our breakthrough therapies have been published in scientific journals and presented at major medical conferences.